NCT00313300

Safety Study of Apixaban in Recent Acute Coronary Syndrome

A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,741 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.

Conditions

• Acute Coronary Syndrome (ACS)

Interventions

Type	Name	Description
DRUG	Apixaban	Tablets, Oral, 2.5 mg, twice daily, 26 weeks
DRUG	Apixaban	Tablets, Oral, 10 mg, once daily, 26 weeks
DRUG	Placebo	Tablets, Oral, 0, twice daily, 26 weeks
DRUG	Apixaban	Tablets, Oral 10 mg, twice daily, 26 weeks

Timeline

• Start date: 2006-05-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2006-04-12
• Last updated: 2015-12-30
• Results posted: 2015-10-15

Locations

151 sites across 14 countries: United States, Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Poland, Russia, Spain, Sweden, United Kingdom